Pulmonx Corp’s Earnings Call Contradictions: Sales Turnover as Growth Culprit, 2026 Recovery Timeline Shifts

Date of Call: Mar 4, 2026

Financials Results

• Revenue: Q4: $22.6M, down 5% YOY; Full Year: $90.5M, up 8% YOY.
• EPS: Q4: Loss of $0.25 per share vs. loss of $0.33 prior year; Full Year: Loss of $1.33 per share.
• Gross Margin: Q4: 77.6% vs. 74% prior year; Full Year: 74%.
• Operating Margin: Not explicitly provided as a percentage; operating loss context implied.

Guidance:

• Revenue for full year 2026 expected in the range of $90M to $92M.
• Expect return to YOY growth in both U.S. and international businesses starting in the back half of the year.
• Gross margin for full year 2026 expected to be approximately 75%.
• Operating expenses for full year 2026 expected between $113M and $115M, inclusive of ~$21M noncash stock-based compensation.
• Committed to reducing annual cash burn from $32M in 2025 to $23M in 2026 (~30% reduction).

Business Commentary:

Weak U.S. Revenue Performance:

• U.S. revenue in Q4 2025 was $14.1 million, a 11% decrease from $15.9 million in the same period last year. For the full year 2025, U.S. revenue was $57 million, a 1% increase over the prior year.
• The underperformance was largely due to internal operational and executional challenges, including the U.S. sales organization being stretched across too many competing initiatives, disruptive changes in Territory Manager roles, and a suboptimal sales incentive structure, leading to significant turnover.

Cost Restructuring and Financial Outlook:

• Operating expenses were reduced by over 10% as part of a cost restructuring initiative, with a focus on balancing expense management with continued investment in key growth initiatives.
• The company closed on a $60 million credit facility, which strengthens the balance sheet and provides financial flexibility, aiming to reduce annual cash burn from $32 million in 2025 to $23 million in 2026.

International Revenue Growth:

• International revenue in Q4 2025 was $8.5 million, an 8% increase from $7.9 million the previous year, with a 23% increase for the full year 2025.
• Growth was driven by strength in major European markets, although offset by a lack of sales to the distributor in China due to pending registration certificate renewal.

AeriSeal and Clinical Trial Progress:

• Enrollment momentum in the CONVERT II pivotal trial for AeriSeal is accelerating, with the trial designed to evaluate the safety and effectiveness of the AeriSeal system.
• The trial is expected to be completed in 2027, potentially expanding the total addressable market by an estimated 20% globally.

Commercial Strategy Refinement:

• The company is refocusing the U.S. sales team on a streamlined set of high-impact mandates, emphasizing clinical performance and engagement with pulmonary service line directors.
• This strategy aims to improve customer continuity and account management, with expectations for U.S. sales growth to resume in the back half of 2026.

Sentiment Analysis:

Overall Tone: Positive

• "We remain confident in the business and are excited to rebuild momentum..." "I am confident that we have the right strategy and the right people in place to execute." "We have already begun taking decisive action to fix it." "Our experience consistently shows that frontline clinical buy-in is the foundation of every high-performing center."

Q&A:

• Question from John Young (Canaccord): Could you just tell us the percentage of the sales force overall that turned over in Q4? And when did you start hiring and complete that hiring of the new reps?
  Response: Turnover was directionally on the order of half of the sales organization across the year, not just Q4. Hiring for openings has now been completed, with nearly all positions filled.

• Question from John Young (Canaccord): Can you talk about maybe some color on how you're incentivizing sales now? And what are the focused sales strategies now in the U.S.?
  Response: Incentive plan and quota allocation have been revised from the 2025 anomaly. The 2026 plan is viewed as reasonable and based on elements that have worked in the past, focusing on high-impact mandates like clinical champions and service line administrators.

• Question from Jason Bednar (Piper Sandler): Why wouldn't the growth come back sooner now that the sales force is fully in place?
  Response: Growth is expected in the back half due to starting from a steep decline, some new reps needing time to ramp up, and the softness of the prior year's performance, despite a senior/junior rep structure to accelerate learning.

• Question from Jason Bednar (Piper Sandler): Can you expand upon what changed to reduce the cost structure by 10%? What does the fixed vs. variable cost structure look like now?
  Response: The ~10% reduction is in recurring costs, primarily from G&A and marketing, while preserving investment in sales and R&D. Restructuring costs are being incurred this year. The guide implies a 7% to 9% decrease in operating expenses excluding stock-based comp, positioning the company for operating leverage.

• Question from Rick Wise / Annie (Stifel): How do you plan to balance AeriSeal trial investment with U.S. sales organization investments and extending the cash runway?
  Response: Clinical trial execution costs are not a major portion of annual burn. Realignment of clinical leadership and adding trial experts have been done to optimize enrollment without pressuring commercial spending. The overall burn reduction is focused on achieving.

• Question from Rick Wise / Annie (Stifel): How are you thinking about the company's longer-term growth potential?
  Response: The intention is to return the growth profile to a much better place, aiming for substantial improvement. 2026 guidance implies moving to double-digit global growth by the end of the year.

• Question from Frank Takkinen / Nelson (Lake Street Capital Markets): Was there anything fundamental from a market penetration perspective that surprised you as challenging?
  Response: The macro market is a net positive with increasing activity and investment in pulmonary services. Short-term pressures are manageable, and the overall environment is favorable for the company's procedures.

• Question from Frank Takkinen / Nelson (Lake Street Capital Markets): Is the LungTraX Detect program being shelved or deprioritized?
  Response: It is not being deemphasized but is being focused in certain situations where it fits well, such as in larger systems with appropriate profiles. It is helpful for patient identification in targeted accounts.

• Question from Larry Biegelsen / Simran (Wells Fargo): How are you thinking about the ramp in terms of months to productivity for new reps and what indicators should we watch?
  Response: Typically 6 to 9 months for a new territory to ramp, but the timing is staggered. The best indicator is U.S. sales performance, with guidance expecting a gradual step-up from mid/high single-digit declines in Q1 to high single-digit growth in Q4.

• Question from Larry Biegelsen / Simran (Wells Fargo): What is the status and contribution from Japan and China in 2026?
  Response: Japan's post-approval study is contributing revenue but is not a meaningful growth driver for 2026; commercialization is expected the following year. China sales, less than 5% of global revenue, were largely in H1 2025; shipments are expected to resume in H2 2026, creating a timing mismatch for YOY growth optics.

Contradiction Point 1

Root Cause of U.S. Growth Deceleration

Specific cause (people vs. structural) was previously unidentified but is now attributed to sales force turnover.

John Young (Canaccord) - John Young (Canaccord)

20260305-2025 Q4: Turnover occurred across the entire year, not just Q4, and was directionally on the order of half of the sales organization. - Glendon French(CEO)

What was the sales force turnover percentage in Q4, when did the hiring of new reps start and complete, and could you discuss the current sales incentives and focused strategies in the U.S.? - John Young (Canaccord)

20251113-2025 Q3: The CEO is not comfortable speculating on the specific causes (people vs. structural) at this time. - Glendon French(CEO)

Contradiction Point 2

Timeline for U.S. Sales Growth Recovery

Growth recovery timeline shifts from being vague to a specific back-half 2026 target.

What is the company's guidance for the next quarter and potential impacts on earnings? - Jason Bednar (Piper Sandler)

20260305-2025 Q4: The expectation is for U.S. sales growth to resume in the back half of 2026, with a gradual ramp-up. - Glendon French(CEO)

Why hasn't U.S. growth returned sooner with the sales force fully in place, and can you elaborate on the ~10% cost structure reduction, including the sources of savings and the updated fixed vs. variable cost structure? - John Young (Canaccord)

20251113-2025 Q3: The range represents what they are confident they can achieve, with more details to be provided on the Q4 call. - Derrick Sung(CFO)

Contradiction Point 3

Nature of Cost Structure Improvements

Cost reduction is framed as a reallocation (not external financing) versus being a new strategic focus.

Jason Bednar (Piper Sandler) - Jason Bednar (Piper Sandler)

20260305-2025 Q4: The ~10% reduction refers to recurring costs across the board. Savings primarily came from G&A and marketing expenses. - Derrick Sung(CFO)

Why isn't U.S. growth returning sooner with the sales force fully in place, and can you elaborate on the ~10% cost structure reduction, including the sources of savings and the new fixed vs. variable cost structure? - Jason Bednar (Piper Sandler)

20251113-2025 Q3: Extending the cash runway involves reallocating expenses and focusing investments on areas with the highest return on capital. - Derrick Sung(CFO)

Contradiction Point 4

Strategy for Improving Underperforming U.S. Territories

Specific action plan promised but delayed, with no details provided in later call.

John Young (Canaccord) - John Young (Canaccord)

20260305-2025 Q4: The issue in 2025 was the allocation of quotas and the amount of quota... For 2026, the company has reverted to a tested and well-understood incentive plan design and quota allocation method. - Glendon French(CEO)

What was the sales force turnover percentage in Q4, when were the new reps hired, and what are the current U.S. sales incentives and strategies? - Annie (Stifel)

2025Q3: He indicated that if there are low-hanging fruit opportunities, they will be pursued, while also driving more patients and increasing same-store sales broadly. - Glenn French(CEO)

Contradiction Point 5

Overall Growth Guidance

2026 guidance implies a move to double-digit global growth by year-end, contrasting with a conservative baseline in 2025Q2.

Annie (Stifel, for Rick Wise) - Annie (Stifel, for Rick Wise)

20260305-2025 Q4: 2026 guidance implies a move to double-digit global growth by the end of the year. - Glendon French(CEO) & Derrick Sung(CFO)

How do you plan to balance investment in the AeriSeal CONVERT II trial, U.S. sales organization investments, and extending the cash runway, while also pursuing longer-term growth aspirations? - Frederick Allen Wise (Stifel, Nicolaus & Company, Incorporated, Research Division)

2025Q2: The guidance is framed conservatively, assuming current growth trends continue. - Steven S. Williamson(CEO)